Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 75
Filter
1.
Lancet ; 354(9187): 1337-41, 1999 Oct 16.
Article in English | MEDLINE | ID: mdl-10533862

ABSTRACT

BACKGROUND: There is controversy as to whether haemodialysis-membrane biocompatibility (ie, the potential to activate complement and neutrophils) influences mortality of patients with acute renal failure. We did a prospective randomised multicentre trial in patients with dialysis-dependent acute renal failure treated with two different types of low-flux membrane. METHODS: 180 patients with acute renal failure were randomly assigned bioincompatible Cuprophan (n=90) or polymethyl-methacrylate (n=90) membranes. The main outcome was survival 14 days after the end of therapy (treatment success). Odds ratios for survival were calculated and the two groups were compared by Fisher's exact test. Analyses were based on patients treated according to protocol (76 Cuprophan, 84 polymethyl methacrylate). FINDINGS: At the start of dialysis, the groups did not differ significantly in age, sex, severity of illness (as calculated by APACHE II scores), prevalence of oliguria, or biochemical measures of acute renal failure. 44 patients (58% [95% CI 46-69]) assigned Cuprophan membranes and 50 patients (60% [48-70]) assigned polymethyl-methacrylate membranes survived. The odds ratio for treatment failure on Cuprophan compared with polymethyl-methacrylate membranes was 1.07 (0.54-2.11; p=0.87). No difference between Cuprophan and polymethyl-methacrylate membranes was detected when the analysis was adjusted for age and APACHE II score. 18 patients in the Cuprophan group and 20 in the polymethyl-methacrylate group had clinical complications of therapy (mainly hypotension). INTERPRETATION: There were no differences in outcome for patients with dialysis-dependent acute renal failure between those treated with Cuprophan membranes and those treated with polymethyl-methacrylate membranes.


Subject(s)
Acute Kidney Injury/mortality , Acute Kidney Injury/therapy , Biocompatible Materials , Membranes, Artificial , Renal Dialysis/instrumentation , APACHE , Acute Kidney Injury/classification , Acute Kidney Injury/etiology , Cellulose/analogs & derivatives , Female , Humans , Logistic Models , Male , Polymethyl Methacrylate , Treatment Outcome
5.
Br J Haematol ; 97(3): 544-6, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9207396

ABSTRACT

We report the case of a 42-year-old woman with chronic recurrent thrombotic thrombocytopenic purpura. Therapy with corticosteroids, high-dose immunoglobulins, plasma exchange and cyclophosphamide only induced short-lasting remissions during a course of almost 3 months. Following a severe relapse on day 90 after the start of symptoms, polychemotherapy with cyclophosphamide. adriamycin, vincristine and prednisolone (CHOP) was begun. After two cycles of CHOP the patient has stayed in complete remission, with normal platelet counts for more than 9 months to date.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Purpura, Thrombotic Thrombocytopenic/drug therapy , Adult , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Prednisone/therapeutic use , Recurrence , Vincristine/therapeutic use
6.
Ther Apher ; 1(2): 131-4, 1997 May.
Article in English | MEDLINE | ID: mdl-10225758

ABSTRACT

Long-term survival of patients with polycythemia vera (PV) is essentially determined by the ability to reduce the risk of thromboembolic complications resulting from the altered rheological conditions by the high red blood cell (RBC) mass of these patients. RBC depletion to normal hematocrit (Hct) values is the first line therapy and should be preferred to chemotherapy (or P32) because of the long-term risk of acute leukemia or other secondary malignancies. RBC depletion is accomplished much more effectively and rapidly by erythrocytapheresis (EA) than by repeated phlebotomies and has been shown to be well tolerated and accepted by the patients (8). The main indications for EA for a PV patient (often newly diagnosed) are high risk Hct values of >55-60% that can be reduced to the normal range within 1-2 h. The long-lasting effect (median interval between 2 EA treatments: ca. 6 months) is partially the result of the massive loss of iron, a growth factor for erythropoesis. This has been shown by in vitro studies in erythroid progenitor cells of PV patients before and after EA (11). The advantages and possible disadvantages of EA treatment are discussed.


Subject(s)
Cytapheresis/methods , Polycythemia Vera/therapy , Erythroid Precursor Cells , Hematocrit , Humans , Phlebotomy , Treatment Outcome
9.
Proc Assoc Am Physicians ; 108(2): 134-9, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8705733

ABSTRACT

Goodpasture syndrome is an often fatal autoimmune disease associated with glomerulonephritis and/or pulmonary hemorrhage. The clinical manifestations of this disease correlate well with the presence of circulating antiglomerular basement membrane (GBM) autoantibodies. The primary target antigen in glomerular and alveolar basement membranes is thought to be the alpha 3 chain of type IV collagen. Nearly all that is known about anti-GBM antibodies in humans comes from work on unbound circulating antibody. We recently had the unique and rare opportunity to obtain early postmortem antibody and tissues from a patient who died with catastrophic Goodpasture syndrome. The specificity of circulating, kidney-bound and lung-bound autoantibodies from this patient was evaluated against a variety of purified basement membrane constituents. The results indicate that the primary target for the circulating and tissue-bound autoantibodies is the NC1 domain of the alpha 3(IV) chain of type IV collagen. Additionally, all the antibodies recognize a cryptic epitope/s on the alpha 3(IV)NC1 hexamer. Furthermore, tissue-bound and circulating antibodies compete with one another for overlapping epitopes on the antigen. These findings demonstrate that circulating autoantibodies in Goodpasture syndrome are highly representative of those bound to organ tissues, strengthening the notion that pathogenic autoantibodies are targeted to the alpha 3(IV)NC1 collagen, and that previous reports of findings in the circulation may be applicable to tissue injury.


Subject(s)
Anti-Glomerular Basement Membrane Disease/immunology , Autoantibodies/immunology , Collagen/immunology , Adolescent , Antibodies/immunology , Antibody Specificity , Binding Sites , Epitope Mapping , Humans , Immunoglobulin G/immunology , Kidney/immunology , Kidney/pathology , Lung/immunology , Lung/pathology , Male , Recombinant Proteins/immunology
10.
Langenbecks Arch Chir ; 380(2): 82-9, 1995.
Article in German | MEDLINE | ID: mdl-7760655

ABSTRACT

Investigations of changes in activity of renin and blood pressure after reperfusion of the kidney transplant using HTK solution were carried out by means of an autologous, heterotopic model of kidney transplantation applied to dogs. Duration of cold ischemia was 48 h. According to variations in the composition of the HTK perfusion solution three test groups were set up. During the first 20 min after recirculation in each test group the renal venous and arterial renin activities were measured. Parallel to renin activity, the arterial blood pressure was recorded. During the first few minutes following recirculation of the kidney transplant the renin levels in the venous blood of the kidney were higher in test group 1 (HTK solution, perfusion height 120 cm) than in either of the other two, showing a median maximal increase of 195 ng/ml.h. In test group 2 the maximal venous renin concentration fell to 145 ng/ml.h, while graphs take a more uniform course. Test group 3 (HTK/tryptophan) differed from the others in having further improved renin values. After the 7.5 min of observation normal venous renin concentrations were measured following earlier values for maximal increase between 23.1 ng/ml.h and 120 ng/ml.h (median 61.5 ng/ml.h). The best reperfusion of the kidney was observed in the tryptophan group, albeit without any recognizable positive effects on the other renal functions. Initially low renin values do not necessarily correlate with a smooth postoperative renal function and vice versa. Initial renin values cannot provide a secure basis for predicting instant as well as long-term postoperative functions.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Aspartic Acid/pharmacology , Blood Pressure/drug effects , Kidney Transplantation/physiology , Organ Preservation , Renin/blood , Tryptophan/pharmacology , Animals , Blood Pressure/physiology , Dogs , Glucose/pharmacology , Kidney/blood supply , Kidney Function Tests , Mannitol/pharmacology , Potassium Chloride/pharmacology , Procaine/pharmacology , Reperfusion Injury/physiopathology , Transplantation, Autologous , Transplantation, Heterotopic/physiology
13.
Monatsschr Kinderheilkd ; 141(3): 219-22, 1993 Mar.
Article in German | MEDLINE | ID: mdl-8474469

ABSTRACT

A 4 month old girl developed a severe hemolytic uremic syndrome (HUS) following pneumococcal sepsis and meningitis. As a result of the hemolytic anemia and thrombocytopenia with associated gastrointestinal bleeding several red blood cell and thrombocyte transfusions became necessary. No plasma was transfused to the patient and all cellular blood components to be transfused were washed thoroughly in order to avoid the administration of eventually dangerous donor anti-T antibodies. Continuous peritoneal dialysis was performed for 23 days until sufficient spontaneous urine production was resumed. From the start of increased hemolysis T-transformation of the patient's red blood cells could be shown; bacterial neuraminidase was proven in the patient's serum, which could be neutralized in vitro by a commercial intravenous IgG preparation. The direct Coombs-Test was negative and no significant amounts of anti-T antibodies were detectable in the patient's serum at any stage of the disease. Our observation suggest that the T-transformation itself has caused the increased hemolysis and not an antigen-antibody (T-anti-T) reaction. In cases of HUS und proven T-transformation, intravenous IgG preparations should be tried therapeutically to inhibit the bacterial neuraminidase.


Subject(s)
Autoantibodies/analysis , Bacteremia/immunology , Hemolytic-Uremic Syndrome/immunology , Lymphocyte Activation/immunology , Meningitis, Pneumococcal/immunology , T-Lymphocytes/immunology , Antigen-Antibody Reactions/immunology , Bacteremia/therapy , Blood Platelets/immunology , Coombs Test , Erythrocytes/immunology , Female , Hemolytic-Uremic Syndrome/therapy , Humans , Infant , Meningitis, Pneumococcal/therapy , Neuraminidase/blood
14.
Dtsch Med Wochenschr ; 117(38): 1434-8, 1992 Sep 18.
Article in German | MEDLINE | ID: mdl-1526205

ABSTRACT

A 24-year-old woman had been in full remission of an acute myeloid leukaemia since 1988, but she required regular erythrocyte and platelet transfusions for pancytopenia. To counteract a progressive siderophilia due to the transfusions (ferritin levels of about 10,000 ng/ml) deferoxamine was intermittently given intravenously (5 g after each transfusion). Seven months after the start of this treatment the patient was hospitalized because of severe left-sided facial pain as well as reddening and swelling in the periorbital region. As maxillary and frontal sinusitis was suspected, antibiotics were administered (at first three times daily 2.2 g amoxicillin and clavulanic acid, then two times daily 300 mg rifampicin and 200 mg ciprofloxacin). Nonetheless, orbital phlegmon developed within a few days with protrusion and blindness of the left eye necessitating a decompression operation. Material obtained at operation revealed rhinocerebral mucormycosis. After 3 weeks of antimycotic treatment with both amphotericin B (1 mg/kg.d) and flucytosine (150 mg/kg.d) the mucormycosis healed without the necessity of extensive and disfiguring removal of necrotic tissue. But the blindness in the left eye, caused by occlusion of the central artery, was irreversible.


Subject(s)
Brain Diseases/etiology , Deferoxamine/adverse effects , Mucormycosis/etiology , Paranasal Sinus Diseases/etiology , Rhizopus , Adult , Blindness/diagnosis , Blindness/etiology , Blindness/therapy , Brain Diseases/diagnosis , Brain Diseases/therapy , Cellulitis/diagnosis , Cellulitis/etiology , Cellulitis/therapy , Combined Modality Therapy , Deferoxamine/administration & dosage , Female , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Mucormycosis/diagnosis , Mucormycosis/therapy , Orbital Diseases/diagnosis , Orbital Diseases/etiology , Orbital Diseases/therapy , Pancytopenia/drug therapy , Pancytopenia/etiology , Paranasal Sinus Diseases/diagnosis , Paranasal Sinus Diseases/therapy , Time Factors
15.
Vox Sang ; 61(4): 258-64, 1991.
Article in English | MEDLINE | ID: mdl-1776243

ABSTRACT

The need of fresh-frozen donor plasma with a low level of anti-T has been emphasized recently. Anti-T, as administered by transfusion of fresh-frozen plasma, has been accused repeatedly of enhancing hemolysis in septic children with T transformation of red cells. Therefore, a new hemolysis test for the quantification of anti-T in human serum has been developed. With our test, anti-T-poor plasma donors can be found. Additional results raise substantial doubt as to the pathogenetic role of anti-T in the development of the hemolytic-uremic syndrome, found in septic children with red-cell T transformation. It is impossible to predict in vivo hemolysis induced by anti-T knowing the temperature characteristics and the ionic conditions causing this antibody to mediate hemolysis in vitro. Obviously, T transformation itself plays the major pathogenetic role in these patients, and not the presence of anti-T. In the case of disseminated intravascular coagulation, a content of anti-T cannot be construed as prohibiting transfusion of fresh-frozen plasma to such patients.


Subject(s)
Antibodies/analysis , Antigens, Viral, Tumor/immunology , Erythrocytes/immunology , Antibodies/isolation & purification , Biological Assay , Hemolytic-Uremic Syndrome/immunology , Humans , Lectins , Osmotic Fragility , Temperature
16.
Klin Wochenschr ; 68(23): 1183-8, 1990 Dec 04.
Article in English | MEDLINE | ID: mdl-2280582

ABSTRACT

Plasma exchange has proven to be effective in diseases of established or presumed autoimmune etiology as well as in hyperviscosity syndromes and some rare metabolic disorders. Its application is thought to be relatively safe; nevertheless, severe complications may occur. We therefore analyzed the complications of 291 exchanges in 39 patients with neurological diseases. Minor complications developed in 4.8% and major complications in 2.7% of procedures, including one death. Severe infections and technical problems have been the most serious side effects, sometimes followed by organ failure or even death.


Subject(s)
Nervous System Diseases/complications , Plasma Exchange/adverse effects , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Multiple Sclerosis/complications , Myasthenia Gravis/complications , Polyradiculoneuropathy/complications
17.
Dtsch Med Wochenschr ; 115(34): 1270-5, 1990 Aug 24.
Article in German | MEDLINE | ID: mdl-2202575

ABSTRACT

Haemolytic uraemic syndrome was diagnosed in a 36-year-old woman with acute renal failure (creatinine 10.5 mg/dl), haemolytic anaemia (haemoglobin 9.7 g/dl, lactate dehydrogenase 1926 U/l) and thrombopenia (98,000/microliters). After initial plasmaphereses and high doses of furosemide all symptoms disappeared within three weeks. The lectin tests demonstrated that the illness was connected with the liberation of T-crypt-antigen (Thomsen-Friedenreich antigen) on the erythrocytes. This special form of the haemolytic uraemic syndrome (neuraminidase-induced haemolytic uraemic syndrome) has previously been observed almost exclusively in children. However, for diagnosis and differentiation of haemolytic uraemic syndromes the presence of liberated T-antigen on erythrocytes should also be tested for in adults.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate , Disaccharides/blood , Hemolytic-Uremic Syndrome/diagnosis , Isoantigens/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/therapy , Adult , Blood Transfusion , Combined Modality Therapy , Diagnosis, Differential , Drug Therapy, Combination , Erythrocytes/immunology , Female , Hemolytic-Uremic Syndrome/etiology , Hemolytic-Uremic Syndrome/therapy , Humans , Plasma , Plasmapheresis
SELECTION OF CITATIONS
SEARCH DETAIL